Determinants of the Recommended Phase 2 Dose of Molecular Targeted Agents

Cancer - United States
doi 10.1002/cncr.30579
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Clinical Benefit in Phase-I Trials of Novel Molecularly Targeted Agents: Does Dose Matter?

British Journal of Cancer
Cancer ResearchOncology
2009English

Recommended Dose of Anti-D Immunoglobulin.

BMJ
1993English

Recommended Environmental Dose Calculation Methods and Hanford-Specific Parameters. Revision 2

1993English

Delayed Adverse Events in Phase I Trials of Molecularly Targeted and Cytotoxic Agents

Oncotarget
Oncology
2018English

A Dose-Escalating Phase I of Imatinib Mesylate With Fixed Dose of Metronomic Cyclophosphamide in Targeted Olid Tumours

British Journal of Cancer
Cancer ResearchOncology
2013English

Molecular Targeted Agents--Where We Are and Where We Are Going

Chinese Journal of Cancer
2013English

A Phase I Clinical Trial of Targeted Intraoperative Molecular Imaging for Pulmonary Adenocarcinomas

Annals of Thoracic Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2018English

New BNF Maximum Recommended Dose for Haloperidol

Psychiatric Bulletin
2001English

Unmasking the Molecular Determinants Important for Ca 2+ -Dependent Regulation of Ca v 2.2

Biophysical Journal
Biophysics
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy